pharm edaily

[Lim Jeong-yeo, Edaily Reporter] Shares of Peptron and Oncocross hit their daily upper limits on the Kosdaq on Friday, fueled by growing investor interest in obesity treatments and AI-driven drug development. T&R Biofab also posted strong gains, while Lameditech and AbClon --both recently featured in PharmEDAILY premium content--saw double-digit increases.

(자료=KG제로인 엠피닥터)

Peptron Surges on Obesity Drug Momentum

According to MP Doctor, formerly MarketPoint under KG Zeroin, Peptron rose 29.99% to close at 164,700 won, extending its winning streak to four sessions. While no clear trigger was identified, the stock is widely viewed as a strong obesity-treatment player in the South Korean market.

Peptron is advancing a long-acting drug delivery platform using microsphere technology. Its candidate PT403 is a biobetter of a GLP-1 receptor agonist, targeting diabetes and obesity. It is currently undergoing preclinical toxicity trials. Peptron aims to develop PT403 as the world’s first once-monthly or once-every-two-months treatment.

Inventage Lab, another long-acting therapy developer, also saw gains, jumping 19% to 17,170 won.

“We’re carrying out all development tasks as scheduled,” a Peptron official told PharmEdaily.

AI Drug Developers Rise on Regulatory Tailwinds

Oncocross rallied 29.92% to 11,420 won, benefiting from a broader move among AI drug discovery companies after the U.S. FDA signaled plans to phase out animal testing in favor of AI-based modeling.

SyntekaBio advanced 19.57% to 7,700 won, while Lunit rose 9.4% to 49,450 won.

Oncocross also gained attention after naming physician-scientist Kang Ji-hoon as co-CEO. Kang joined the company in 2020 and has overseen Oncocross’ drug discovery efforts. Prior to joining Oncocross, Kang earned his Ph.D. at Ulsan University and served as an oncologist at Asan Medical Center and Kangbuk Samsung Hospital.

CEO Kim Yi-rang said that Oncocross was invited to speak at the upcoming World Orphan Drug Congress in Boston this month.

T&R Biofab Soars on Personalized Bone Implant Study Results

T&R Biofab surged 24.39% to 4,565 won after announcing positive clinical results for its 3D-printed biodegradable orbital implants and its intention to seek FDA approval.

In a study led by Dr. Sah Ho-seok at Asan Medical Center, T&R Biofab’s implants tailored individually for a total of 40 patients led to almost no surgical adjustments and were shortened the surgery time to an average of just 20 seconds. The implants stimulate natural bone regeneration and are fully absorbed in to body over time. The study results went out in Scientific Reports, published by Nature Portfolio.

The company also expects higher Q1 revenue following its acquisition of cosmetics firm Blisspack.

Lameditech Rises on Laser-Based Diagnostics

Lameditech jumped 21.05% to 8,970 won, buoyed by increased visibility after a previously paywalled PharmEdaily article was released to the public.

Lameditech is the only Korean firm with MFDS approval for a laser-based blood collection device. Its product line, HandyRay, uses painless micro-laser to create tiny openings in the skin for blood sampling, reducing infection risk and eliminating the need for needles. The company plans to expand business into glucose-monitoring market later this year using the same platform technology.

라메디텍 주가추이(자료=KG제로인 엠피닥터)

AbClon Recovers as Fundamentals Gain Focus

AbClon rose 10.56% to 9,320 won after PharmEdaily highlighted its growth potential despite being placed on the Kosdaq’s administrative watchlist for missing the 3 billion won sales requirement.

The company posted 1 billion won in sales through April and is on track to exit the watchlist next year. It also holds around 10 billion won in cash and is advancing its CAR-T therapy AT101.

AbClon also plans to present fresh data on its immunotherapy candidate AM105 at the American Association for Cancer Research (AACR) conference later this month in Chicago.

앱클론 주가추이(자료=KG제로인 엠피닥터)